>
Switch to:

Intec Parent ROE %

: -130.74% (As of Mar. 2021)
View and export this data going back to 1996. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Intec Parent's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2021 was $-16.92 Mil. Intec Parent's average Total Stockholders Equity over the quarter that ended in Mar. 2021 was $12.94 Mil. Therefore, Intec Parent's annualized ROE % for the quarter that ended in Mar. 2021 was -130.74%.

The historical rank and industry rank for Intec Parent's ROE % or its related term are showing as below:

NAS:NTEC' s ROE % Range Over the Past 10 Years
Min: -146.28   Med: -70.94   Max: -31.9
Current: -97.42

-146.28
-31.9

During the past 8 years, Intec Parent's highest ROE % was -31.90%. The lowest was -146.28%. And the median was -70.94%.

NAS:NTEC's ROE % is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: -68.79 vs. NAS:NTEC: -97.42 )

Intec Parent ROE % Historical Data

The historical data trend for Intec Parent's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Premium Member Only Premium Member Only Premium Member Only -45.89 -70.94 -77.52 -146.28 -108.39

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.21 -77.56 -87.34 -87.61 -130.74

Competitive Comparison

For the Biotechnology subindustry, Intec Parent's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intec Parent ROE % Distribution

For the Biotechnology industry and Healthcare sector, Intec Parent's ROE % distribution charts can be found below:

* The bar in red indicates where Intec Parent's ROE % falls into.



Intec Parent ROE % Calculation

Intec Parent's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-14.128/( (11.535+14.533)/ 2 )
=-14.128/13.034
=-108.39 %

Intec Parent's annualized ROE % for the quarter that ended in Mar. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Mar. 2021 )/( (Total Stockholders Equity (Q: Dec. 2020 )+Total Stockholders Equity (Q: Mar. 2021 ))/ count )
=-16.916/( (14.533+11.344)/ 2 )
=-16.916/12.9385
=-130.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2021) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Intec Parent  (NAS:NTEC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-16.916/12.9385
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-16.916 / 0)*(0 / 19.163)*(19.163 / 12.9385)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.4811
=ROA %*Equity Multiplier
=N/A %*1.4811
=-130.74 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-16.916/12.9385
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-16.916 / -16.836) * (-16.836 / -16.712) * (-16.712 / 0) * (0 / 19.163) * (19.163 / 12.9385)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0048 * 1.0074 * N/A % * 0 * 1.4811
=-130.74 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2021) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Intec Parent ROE % Related Terms

Thank you for viewing the detailed overview of Intec Parent's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent Business Description

Intec Parent logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Linscott Walt Addison officer: Chief Business Officer 1860 MONTREAL ROAD TUCKER GA 30084
Sassi Nir officer: Chief Financial Officer 3 ELUL STREET, APT. 6 MODIIN L3 7176397
Navon Nadav officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Maddaluna Anthony J director PFIZER INC. ATTN CORPORATE SECRETARY 235 RAST 42ND STREET NEW YORK NY 10017
Hayes William B director 231 MAPLE AVENUE BURLINGTON NC 27215
Pomerantz Roger director 711 HARVEST HILL ROAD CHALFONT PA 18914
Karah Hila director 9 HALAMISH STREET CAESAREA INDUSTRIAL PARK CAESAREA L3 38900
Kozarich John W director 10275 SCIENCE CENTER DR SAN DIEGO CA 92121
Meckler Jeffrey A director, officer: Chief Executive Officer 740 BROADWAY 9TH FLOOR NEW YORK NY 10003
Gendreau R Michael officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Oren Dan 10 percent owner 1 DEXCEL STREET OR AKIVA L3 30600000
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET OR AKIVA L3 3060000
Bianco Gil director 7 HAORANIM STREET BAZRA L3 60944
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)